Drug Database
PE

PEG IFN alpha-2a (CAP/CTM HCV 2.0)

✓ Approved

Roche · 辅助诊断 · 辅助诊断

什么是 PEG IFN alpha-2a?

PEG IFN alpha-2a 是一种辅助诊断,由Roche研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

商品名CAP/CTM HCV 2.0
公司Roche
药物类别辅助诊断
给药途径Others
状态Approved

相关研究文献

PubMedBMC veterinary research2026-09-10

Development of an inactivated, oral immunogenic product against post-weaning colibacillosis caused by enterotoxigenic Escherichia coli in piglets.

Inglesi Alessia A, Filipe Joel J, Valli Giulia G, Riva Federica F et al.

Post-weaning diarrhea (PWD) caused by enterotoxigenic Escherichia coli (ETEC) expressing F4 and F18 fimbriae remains a major challenge in pig production, contributing to economic losses and increased antimicrobial use. This study aimed to preliminary evaluate the immunogenic potential of an orally administered formulation comprising heat-inactivated ETEC strains expressing F4 and F18 fimbriae, combined with low-dose recombinant human interferon-alpha (IFN-α) as a mucosal adjuvant, in piglets. Piglets from two different litters were allocated into two experimental groups: a treated group (T) receiving the inactivated ETEC formulation with IFN-α for 26 days, and a control group (C) receiving only IFN-α. According to the farmer, the sows had not been vaccinated. Immune responses were evaluated in the sows colostrum and piglet serum, saliva, and feces by ELISA. In mesenteric lymph nodes anti-F4/F18 IgA and IgG antibodies were quantified by ELISPOT. The inactivated product preserved fimbrial antigenicity and remained sterile. Colostrum from both sows displayed elevated levels of fimbriae-specific IgA and IgG despite neither sow being vaccinated against E. coli. Treated piglets showed a transient serum IgA increase against F4 whereas serum IgG levels were often comparable to the controls. Notably, elevated mucosal IgA responses were observed in saliva and feces against both F4 and F18 (P < 0.01) in T group, accompanied by enhanced IgA-secreting B-cell activity in mesenteric lymph nodes. ELISA validation confirmed high assay reproducibility (R² > 0.98; CV < 10%). ELISPOT analysis underscored the adjuvant role of F4 and IFN-α in stimulating mucosal immunity. Our preliminary findings may represent a promising strategy to control PWD and reduce antimicrobial use in pig production.

PMID 42717342
阅读全文 →
PubMedStress biology2026-09-10

Lycopene mitigates T-2 toxin-induced systemic inflammation and oxidative stress in association with gut microbiota and SCFAs regulation in mice.

Adam Saber Y SY, Ennab Wael W, Zhu Cuipeng C, Yuan Long L et al.

T-2 toxin is a trichothecene mycotoxin produced by Fusarium species and can cause disease after contaminated food or feed ingestion. This study aimed to investigate the impact of lycopene (Ly) on systemic inflammation, oxidative stress, and dysbiosis in mice exposed to T-2 toxin. A total of 20 male BALB/c mice (6 weeks old, weighing 23.5 ± 0.32 g) randomly divided into four groups (n = 5): Control (Cont), Ly, T-2, and T-2 + Ly groups. Findings revealed that Ly enhanced the body weight, feedd, and water intake that have been reduced by T-2. Ly increased the villus height (VH) and VH: crypt depth (CD) and decreased CD and villus width (VW) in ileum compared to the T-2 group. In alpha diversity, Staphylococcus and Corynebacterium were the most prevalent in Cont group; Staphylococcus, and Lactobacillus, were the most prevalent in T-2 group; Candidatus-Arthromitus and Staphylococcus were the most prevalent in T-2 + Ly group. Moreover, T-2 mice had significantly (p < 0.05) greater levels of interleukin-1 beta (IL-1β), interferon gamma (IFN-γ), Interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-α) than Cont, while the Ly significantly (p < 0.05) lowered their concentration. The T-2 mice had significantly (p < 0.05) higher levels of reactive oxygen species (ROS) and malondialdehyde (MDA), while their catalase (CAT),, glutathione (GSH), adenosine triphosphate (ATP), and superoxide dismutase 1(SOD1) activities were significantly (p < 0.05) lower than Cont. Ly significantly (p < 0.05) restored their concentration. Moreover, there was a significant reduction (p < 0.05) of hexanoic, butyric, acetic, pentanoic, and Heptanoic acids in the T-2 mice compared to Cont. In contrast, treatment with Ly was found to significantly restore their levels compared to T-2 group. We conclude that Ly administration in the context of T-2-induced toxicity may help attenuate systemic oxidative stress and inflammation, possibly through modulation of gut microbiota and fecal short-chain fatty acids (SCFAs).

PMID 42720699
阅读全文 →
PubMedRegenerative biomaterials2026-09-10

Synergistic effects of berberine and adipose stem cells in a silk fibroin-PEG hydrogel for diabetic wound healing via macrophage polarization modulation.

Hu Xiaohao X, Xu Jia J, Zhong Yanping Y, Zheng Weihao W et al.

Diabetic wound repair remains a considerable clinical challenge, largely due to the limited efficacy of current therapies. Herein, we engineered a novel silk fibroin (SF)-polyethylene glycol (PEG) hydrogel (SPB) incorporated with berberine (BBR) and adipose-derived stem cells (ASCs) to synergistically promote diabetic wound healing. By optimizing the physicochemical properties of SPB, we found that a 7:3 SF:PEG ratio provided an ideal balance of pore size (25.83 ± 3.94 μm), mechanical strength (32.33 ± 4.07 kPa) and sustained BBR release. In vitro, SPB significantly enhanced ASC paracrine function, promoting the production of vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), stromal cell-derived factor 1 (SDF-1), platelet-derived growth factor-BB (PDGF-BB), and transforming growth factor beta (TGF-β). Accordingly, SF-based hydrogel system (SPBA) markedly stimulated fibroblast proliferation and migration and enhanced endothelial cell angiogenesis. Moreover, SPBA effectively modulated macrophage repolarization from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype, thereby suppressing inflammation. In vivo, SPBA demonstrated remarkable therapeutic efficacy in diabetic rat full-thickness skin wounds, accelerating wound closure, promoting re-epithelialization, collagen deposition and neovascularization, while reducing local inflammation. These results highlight SPBA as a highly efficient and promising biomaterial strategy for diabetic wound treatment.

PMID 42719899
阅读全文 →
PubMedEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026-09-10

Correction: Postoperative adding-on phenomenon in Lenke 1A/B and 2A/B adolescent idiopathic scoliosis: risk factors and predictive index.

Zhang Hongqi H, Li Tao T, Zhang Gengming G, Deng Ang A et al.

PMID 42720693
阅读全文 →
PubMedDiscover public health2026-09-10

Immunometabolic and RAAS determinants of circulating interferon gamma in an HIV and TB Zambian cohort.

Sidambi Dauyrinah D, Chisompola David D, Lwindi Propheria P, Kaango Arasidah A et al.

Tuberculosis (TB) and human immunodeficiency virus (HIV) remain major global health challenges, particularly in sub-Saharan Africa where co-infection and chronic immune activation are highly prevalent. Interferon-gamma (IFN-γ) plays a central role in host defense against Mycobacterium tuberculosis, yet its determinants in real-world, high-burden populations especially in the context of metabolic and systemic inflammation are not fully understood. This study investigated clinical, inflammatory, and metabolic factors associated with circulating IFN-γ levels in adults in a high HIV/TB burden setting. This was a cross-sectional study of 227 adults attending medical clinic at Livingstone University Teaching Hospital, Zambia. Circulating IFN-γ and a panel of inflammatory, metabolic, and renin-angiotensin-aldosterone system (RAAS) biomarkers were measured. Associations were assessed using simple and multivariable linear regression models, with log transformation applied to skewed variables. Statistical significance was defined as p < 0.05. Among participants (median age 50 years; 64.3% living with HIV), several variables were associated with IFN-γ in unadjusted analyses, including inflammatory cytokines, hs-CRP, angiotensin II, and fasting glucose. However, in multivariable analysis, only female sex (β = -0.440, p = 0.023), fasting glucose (β = 0.153, p = 0.042), angiotensin II (log-transformed) (β = 0.688, p = 0.022), and IL-17 A (log-transformed) (β = 0.332, p = 0.019) remained independently associated with IFN-γ levels. Notably, HIV status, prior tuberculosis infection, hs-CRP, and other inflammatory markers were not independently associated after adjustment. In this high HIV/TB burden population, circulating IFN-γ levels were independently associated with metabolic (fasting glucose), vascular-hormonal (angiotensin II), and immune (IL-17 A) factors, but not with HIV infection or prior TB after adjustment. These findings suggest that IFN-γ may reflect broader immunometabolic and inflammatory processes rather than infection-specific immune activation in treated populations. Longitudinal studies are needed to clarify the prognostic and clinical utility of IFN-γ in integrated chronic disease management. The online version contains supplementary material available at https://doi.org/10.1186/s12982-026-02839-5.

PMID 42718946
阅读全文 →
PubMedAnnals of translational medicine2026-09-10

Individualized pharmacotherapy: background and development.

Jørgensen Jan Trøst JT, Westergaard Niels N

Most drug prescriptions are still based on empiricism and not on solid biological data, which often results in considerable patient variability and, sometimes, low patient benefits. Although variability in patient response to pharmacotherapy has long been recognized, only in recent decades have new molecule analytical methods provided insight into some of the causes, which are often related to somatic or germline genetic variations. Based on this insight, different predictive biomarker tests have been developed to optimize and individualize pharmacotherapy. These biomarker tests are classified as companion diagnostic (CDx) or pharmacogenetic (PGx) tests. In both the United States and Europe, CDx and PGx information is part of the regulatory drug labeling and is included in the Prescribing Information for the individual drugs and biologics. In the United States, this type of information is found in the labeling of more than 400 regulatory-approved drugs and biological products. Despite these measures and the documented clinical utility of CDx and PGx testing, clinical implementation is lagging, especially with regard to PGx. There are various reasons for the lack of testing, such as insufficient education and awareness among healthcare professionals, inadequate access to biomarker testing, regulatory hurdles, and insufficient reimbursements. Although progress has been made in recent years, further efforts are needed to fully realize the potential of individualized pharmacotherapy by integrating the use of predictive biomarkers into routine clinical practice.

PMID 42718847
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多PEG IFN alpha-2a